Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis

Joint Bone Spine

Volumn 80, Issue 6, 2013, Pages 670-671

  Wendling, Daniel ^a   Vidon, Claire ^a   Godfrin Valnet, Marie ^a   Rival, Gilles ^a   Guillot, Xavier ^a   Prati, Clément ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Interstitial lung disease; Pulmonary fibrosis; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ADALIMUMAB; ETANERCEPT; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; CASE REPORT; COUGHING; DISEASE EXACERBATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; INTERSTITIAL LUNG DISEASE; LETTER; LUNG EMPHYSEMA; LUNG FIBROSIS; MALE; PNEUMONIA; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; COMPLICATION; MIDDLE AGED; PULMONARY EMPHYSEMA; PULMONARY FIBROSIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; MALE; MIDDLE AGED; PULMONARY EMPHYSEMA; PULMONARY FIBROSIS;

EID: 84888437182     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2013.03.009     Document Type: Letter

References (11)

1. Hamblin M.J., Horton M.R. Rheumatoid arthritis-associated interstitial lung disease: diagnostic dilemma. Pulm Med 2011, 2011:872120.
2. Brusselle G. Rheumatoid arthritis and interstitial lung disease. Rheumatology (Oxford) 2010, 49:1425-1426.
3. Olson A.L., Swigris J.J., Sprunger D.B., et al. Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2011, 183:372-378.
4. Koduri G., Norton S., Young A., et al. Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 2010, 49:1483-1489.
5. Cottin V., Nunes H., Mouthon L., et al. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum 2011, 63:295-304.
6. Perez-Alvarez R., Perez-de-Lis M., Diaz-Lagares C., et al. Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122cases. Semin Arthritis Rheum 2011, 41:256-264.
7. Hadjinicolaou A.V., Nisar M.K., Bhagat S., et al. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases-a systematic literature review. Rheumatology (Oxford) 2011, 50:2297-2305.
8. Kawashiri S.Y., Kawakami A., Sakamoto N., et al. A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int 2012, 32:4023-4026.
9. Mohr M., Jacobi A.M. Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade. Scand J Rheumatol 2011, 40:400-401.
10. Dixon W.G., Hyrich K.L., Watson K.D., et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010, 69:1086-1091.
11. Pham T., Claudepierre P., Constantin A., et al. Tocilizumab: therapy and safety management. Joint Bone Spine 2010, 77:S3-S100.